Black foot disease of grapevine
Black foot disease of grapevine is a serious phytopathological condition affecting grapevines, particularly in the viticulture industry. The disease is caused by several species of fungi, including Cylindrocarpon and Ilyonectria, which are soil-borne and can persist in vineyard soils for many years.
Symptoms[edit]
The symptoms of Black foot disease are often observed in young grapevines, typically within the first five years of planting. The most characteristic symptom is the presence of black, necrotic lesions on the roots and the base of the trunk, giving the disease its name. Other symptoms include reduced vigor, chlorosis of the leaves, and in severe cases, plant death.
Pathogenesis[edit]
The fungi responsible for Black foot disease are necrotrophic pathogens, meaning they kill host tissue and then feed on the dead cells. The fungi produce mycotoxins that cause cell death, and then use enzymes to break down the dead tissue for nutrients. The disease is spread through the movement of infested soil or infected plant material.
Management[edit]
Management of Black foot disease involves a combination of cultural practices and chemical treatments. Cultural practices include the use of clean planting material, proper site preparation, and good water management. Chemical treatments include the use of fungicides and soil fumigants. However, these treatments are not always effective, and research is ongoing to develop more sustainable management strategies.
Impact[edit]
Black foot disease has a significant impact on the viticulture industry, as it can lead to reduced vineyard productivity and increased replanting costs. The disease is a particular problem in regions with a long history of grapevine cultivation, such as Europe and California, where the pathogens have had time to build up in the soil.
See also[edit]

This article is a plant disease stub. You can help WikiMD by expanding it!
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian